Navigation Links
AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction
Date:7/7/2009

among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are requested by a governmental authority or applicable law.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014 OTC Markets Group ... a biotechnology company, on its approval to list ... on OTCQX®, the best marketplace for established U.S. ... Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... execution of its growth strategy and achievement of ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Pursuit ... selling optimization technology and services for Life Sciences ... “Grading Pharma’s Use of New Commercial Sales Models” ... & Analytics. , The article examines some innovative ... that are being tested in the pharmaceutical market. ...
(Date:8/21/2014)... SoundConnect , a unified communication ... of the nation’s Fastest Growing Private Companies by ... consecutive year. Inc. magazine today ranked SoundConnect NO. ... exclusive ranking of the nation's fastest-growing private companies. ... the most important segment of the economy—America’s independent ...
(Date:8/20/2014)... patented university inventions licensed to biotechnology firms has ... To open these roadblocks, the researchers suggest that ... discovery stage could lead to faster commercialization down ... from discoveries made in university laboratories and licensed ... clinical trials, which have a high failure rate. ...
Breaking Biology Technology:OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 3Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3
... it plans to buy its former parent AT&T , ... opportunities. , ,Drew Petersen, director of legislative affairs for ... is a sign that SBC plans to become a global ... Petersen said tries to present itself as a Midwestern company, ...
... Depressed? , ,Considering we just escaped January a ... the cold, dark and dank weather thats no ... 24 (just one week ago) was the most depressing ... bear an extra psychological burden because of the challenges ...
... biotech company moving to Madison from Chicago is being ... state. , ,Governor Jim Doyle announced earlier this week ... from the Department of Commerce Technology Venture Fund ... programs to help the company purchase new equipment and ...
Cached Biology Technology:SBC merger with AT&T could open opportunities in Wisconsin 2Post-January, tech entrepreneurs have reasons to be depressed 2Post-January, tech entrepreneurs have reasons to be depressed 3Post-January, tech entrepreneurs have reasons to be depressed 4
(Date:8/20/2014)... of Tbingen, Arizona State University, the Wellcome Trust Sanger ... (Swiss TPH) isolated Mycobacterium pinnipedii from skeletons ... old. The pathogen is a relative of the TB ... in humans today. These researchers assume that seals carried ... link to sea lions was unexpected" comments Sebastien Gagneux, ...
(Date:8/20/2014)... Using population-based screening outcomes of approximately 3 million ... four researchers at the University of Massachusetts Medical School, ... (SCID) can be successfully implemented across public health newborn ... in the Aug. 20 issue of the Journal ... showed the rate of SCID in newborns is higher ...
(Date:8/20/2014)... Institutes of Health has awarded the Oklahoma Medical Research ... research on anthrax and the bacteria,s effects on humans. ... Ph.D., and his colleagues have studied the human immune ... Centers for Human Immunology. The original funding came soon ... the heels of the terrorist attacks of Sept. 11, ...
Breaking Biology News(10 mins):Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3$14.5 million grant awarded to continue anthrax studies 2
... Zeneca have found a new way to use solid-state NMR ... spot unwanted polymorphs in pharmaceuticals. Pharmaceuticals companies are constantly ... can actually exist in more than one form or crystal ... different ways. Now researchers at the University of Warwick and ...
... AMES, Iowa -- Forests in the nation,s Upper Midwest ... settlers. And more changes may be coming. That,s ... professor in Iowa State University,s department of Natural Resource ... "There,s been a shift in the entire ecosystem," said ...
... TRADED BROKERAGE TO UTILIZE TITANIUM,S ... SECURITY SOLUTIONS, ... Board: TTNUF), a leading biometric and security solutions,provider announced today that ... 600837). Titanium will install its,Biometrics Access Control System in Haitong,s newly ...
Cached Biology News:NMR researchers unlock hydrogen's secrets to spot polymorphism in pharmaceuticals 2Upper Midwest forests are losing diversity, complexity, ISU study finds 2Titanium Group Announces Contract With Haitong Securities 2Titanium Group Announces Contract With Haitong Securities 3Titanium Group Announces Contract With Haitong Securities 4
... The kit contains 5 ml CELLection Dynabeads ... against the human epithelial antigen EpCAM and ... 5 log enrichment of epithelial tumour cells ... Tumour cells clumps can be enriched from ...
Recombinant Human CCL21/6Ckine (Mucin Stalk Chimera)...
Recombinant Human Erythropoietin (Tissue Culture Grade)...
Acrylamide PAGE 40% Solution, 1 l. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Gel Casting Chemicals....
Biology Products: